Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most
frequent “actionable” alterations in non–small cell lung cancer (NSCLC). Typified by high …

The FLAURA trial established osimertinib, a third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell …

Lung cancer is the second most common malignant tumor and the leading cause of cancer
death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …

Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to
EGFR tyrosine kinase inhibitors (TKIs) and both first-and second-generation TKIs are …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …

Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …

Despite the efficacy of standard-of-care EGFR tyrosine kinase inhibitors (TKIs), erlotinib,
gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance …

Simple Summary The management of non-small cell lung cancer with a common EGFR
mutation has evolved over the past decades. While frontline use of second-or third …

The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …